Sean Burns

Sean Burns

Company: Intellia Therapeutics

Job title: Vice President, Disease Biology


Development of Systemic CRISPR-based Therapeutics 2:45 pm

• Systemic non-viral delivery of CRISPR/Cas9 is a safe and effective way to perform gene editing in vivo • Platform enables potentially curative therapies with a single IV administration • CRISPR-mediated targeted gene insertion provides durable, high-level expression of therapeutic proteins • Non-viral delivery to multiple tissue types opens the door to new therapeutic applicationsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.